Phase 2b RELIEVE UCCD results presented at ACG 2025 show duvakitug’s dose-dependent efficacy and favorable safety in Crohn’s disease.
Vipul Jaraith, MBChB, DPhil
Advertisement
Vipul Jairath, MBChB, DPhil, MRCP, a professor of medicine, epidemiology, and biostatistics at Western University
Articles by Vipul Jaraith, MBChB, DPhil
ANTHEM-UC study findings presented at ACG show efficacy, durability and safety of icotrokinra in adults with moderate-to-severe ulcerative colitis.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on HCPLive
1
SimpleScreen CRC Blood Test Meets Endpoints in Clinical Validation Study
2
Liver Lineup: Bepirovirsen and the Push Toward Functional Cure in Hepatitis B
3
Eplontersen Misses Primary Endpoint in Phase 3 ATTR-CM Trial
4
Biologic Therapy for Asthma and COPD: Real-World Perspectives From APPs
5